915192-39-1

Basic information

• Product Name: BenzeneMethanesulfonaMide, 4-[6,8-dihydro-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-Methyl-
• Synonyms: BenzeneMethanesulfonaMide, 4-[6,8-dihydro-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-Methyl-;[3-methyl-4-[6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-8H-pyrrolo[3,4-g]quinolin-7-yl]phenyl]methanesulfonamide
• CAS NO: 915192-39-1
• Molecular Formula: C₂₃H₁₉F₆N₃O₅S
• Molecular Weight: 563.4694792
• Mol File: 915192-39-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BenzeneMethanesulfonaMide, 4-[6,8-dihydro-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzeneMethanesulfonaMide, 4-[6,8-dihydro-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-Methyl-(915192-39-1)
• EPA Substance Registry System: BenzeneMethanesulfonaMide, 4-[6,8-dihydro-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-Methyl-(915192-39-1)

Safety Data

• Hazardous Substances Data: 915192-39-1(Hazardous Substances Data)

Usage

Classification

Pyrroloquinolinone derivative

Pharmaceutical properties

Potential as an anticancer drug
Promising anti-tumor activity in preclinical studies
Candidate for further development in cancer treatment
Ability to inhibit specific molecular targets
Promising lead compound for drug discovery and development in oncology

Research status

Further research and clinical trials required to evaluate safety and efficacy in cancer patients

Upstream product

• 1185886-65-0 1-{4-[8-hydroxy-6-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-methylphenyl}methanesulfonamide 
• 1185886-66-1 1-{4-[6-hydroxy-8-oxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-methylphenyl}methanesulfonamide 
• 1025402-42-9 C₂₇H₂₅F₆N₃O₆S 
• 915192-30-2 1-(4-amino-3-methylphenyl)methanesulfonamide 
• 915192-31-3 1-(3-methyl-4-nitrophenyl)methanesulfonamide 
• 915192-37-9 5,9-bis(2,2,2-trifluoroethoxy)furo[3,4-g]quinoline-6,8-dione 
• 915192-36-8 5,8-bis(2,2,2-trifluoroethoxy)quinoline-6,7-dicarboxylic acid 
• 915192-35-7 diethyl 5,8-bis(2,2,2-trifluoroethoxy)quinoline-6,7-dicarboxylate 
• 915192-38-0 1-{4-[6,8-dioxo-5,9-bis(2,2,2-trifluoroethoxy)-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl]-3-methylphenyl}methanesulfonamide 
• 39713-32-1 diethyl 5,8-dihydroxyquinoline-6,7-dicarboxylate 
• 141281-38-1 4-(bromomethyl)-2-methyl-1-nitrobenzene 

Relevant articles and documents

Remote electronic control in the regioselective reduction of succinimides: A practical, scalable synthesis of EP4 antagonist MF-310

(Chemical Equation Presented) A practical large-scale chromatography-free synthesis of EP4 antagonist MF-310, a potential new treatment for chronic inflammation, is presented. The synthetic route provided MF-310 as its sodium salt in 10 steps and 17% overall yield from commercially available pyridine dicarboxylate 7. The key features of this sequence include a unique regioselective reduction of succinimide 2 controlled by the electronic properties of a remote pyridine ring, preparation of cyclopropane carboxylic acid 3 via a Corey - Chaykovsky cyclopropanation, and a short synthesis of sulfonamide 5. 2009 American Chemical Society.

QUINOLINE DERIVATIVES AS EP4 ANTAGONISTS

The invention is directed to quinoline derivatives as prostaglandin E type receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. The derivatives have the following structure of formula (I): wherein A and B represents either a nitrogen atom or a CH group with the proviso that they cannot both simultaneously be CH, Q can represent a nitrogen or a carbon atom, and Y and Z are either a nitrogen atom., a N(O) group or a C(R5) group. Pharmaceutical compositions comprising the derivatives of formula (I) are also included.